Merck Phase 3 Trial Met Primary Endpoint at Interim for Hypertension

 WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality

Study to be stopped early and participants will be offered the opportunity to receive WINREVAIR

Second positive phase 3 trial adds to growing body of evidence for WINREVAIR, an activin signaling inhibitor therapy that targets an underlying cause of PAH

https://www.businesswire.com/news/home/20241125959925/en/